VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 198.72 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 198.72K shares, a 470.13% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 246.19K shares.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 201.05K shares, a 296.77% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2026 was 482.10K shares, a 594.52% increase from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 69.42K shares, a 1841.14% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 3.58K shares, a 89.05% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 32.66K shares, a 879.90% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 198.72K shares 10-Q · filed 2026-08-14 | 444.91K shares derived: sum of 2 quarters · filed 2026-08-14 | 645.97K shares derived: sum of 3 quarters · filed 2026-08-14 | 645.97K shares derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | 246.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | 447.25K shares derived: sum of 2 quarters · filed 2026-06-15 | 447.25K shares derived: sum of 3 quarters · filed 2026-06-15 | 482.10K shares 10-K · filed 2026-06-15 | |
| 2025-12-31 | 201.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | 201.05K shares derived: sum of 2 quarters · filed 2026-02-12 | 235.91K shares 10-Q · filed 2026-02-12 | 235.91K shares derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | 34.85K shares 10-Q · filed 2025-11-13 | 34.85K shares derived: sum of 3 quarters · filed 2025-11-13 | 85.53K shares derived: sum of 4 quarters · filed 2025-11-13 | |
| 2025-06-30 | 34.85K shares 10-Q · filed 2025-08-07 | 34.85K shares derived: sum of 2 quarters · filed 2025-08-07 | 85.53K shares derived: sum of 3 quarters · filed 2025-08-07 | 94.69K shares derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | 50.67K shares derived: sum of 2 quarters · filed 2025-06-17 | 59.83K shares derived: sum of 3 quarters · filed 2025-06-17 | 69.42K shares 10-K · filed 2025-06-17 | |
| 2024-12-31 | 50.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | 59.83K shares derived: sum of 2 quarters · filed 2025-02-13 | 69.42K shares 10-Q · filed 2025-02-13 | ||
| 2024-09-30 | 9.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | 18.74K shares 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 9.58K shares 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | 3.58K shares 10-K · filed 2024-06-11 | ||||
| 2023-03-31 | 32.66K shares 10-K · filed 2023-06-28 | ||||
| 2022-03-31 | 3.33K shares 10-K · filed 2023-06-28 | 100.00K shares 10-K · filed 2022-06-23 | |||
| 2021-03-31 | 0.00 shares 10-K · filed 2022-06-23 | ||||
| 2020-03-31 | 0.00 shares 10-K · filed 2021-06-29 | ||||
| 2019-03-31 | 0.00 shares 10-K · filed 2020-06-29 | ||||
| 2018-03-31 | 12.15K shares 10-K · filed 2019-06-25 | -12.15K shares 10-K · filed 2018-06-26 | |||
| 2017-03-31 | 0.00 shares 10-K · filed 2018-06-26 | ||||
| 2016-03-31 | 10.36K shares 10-K · filed 2017-06-29 | ||||
| 2015-03-31 | 2.00K shares 10-K · filed 2016-06-24 | ||||
| 2014-03-31 | 3.95K shares 10-K · filed 2015-06-29 | -79.08K shares 10-K · filed 2014-06-25 | |||
| 2013-03-31 | -29.17K shares 10-K · filed 2014-06-25 | ||||
| 2012-03-31 | -30.00K shares 10-K · filed 2013-07-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |